TY-JUR T1 - ERJ 3月播客：世界TB日JF - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003.E5103-2018 VL - 51是 - 3 SP - 18E5103 A2 - ，Y1 - 2018/03/01 UR - //www.qdcxjkg.com/content/51/3/18E5103.Abstract N2 - 作为3月份问题的一部分，欧洲呼吸期刊在其系列播客中展示了最新的播客。令世界TB日，首席编辑Martin Kolb访谈部分编辑Giovanni Battista Migliori关于以下文章.Borisov SE，Dheda K，Enwerem M等。含床型含床和XDR-TB治疗中的含Beataquiline的方案的有效性和安全性：多期面研究。EUR RESPIR J 2017;49：1700387.Cabibbe Am，Sotgiu G，Izco S等人。基因型和表型M.结核性抗性：指导临床医生规定正确的方案。EUR RESPIR J 2017;50：1702292.falzon d，schünemannhj，harausz e等。世界卫生组织耐药结核病，2016年更新。 Eur Respir J 2017; 49: 1602308.Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.Van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992. ER -